multiple sclerosis

Biogen to pay $22 million to resolve U.S. drug charity kickback probe
Biogen to pay $22 million to resolve U.S. drug charity kickback probe
Reuters
Biogen
MS
kickbacks
Medicare
multiple sclerosis
Flag link:
Roche's MS blockbuster Ocrevus, facing new Novartis competition, scores FDA nod for more-convenient infusion
Roche's MS blockbuster Ocrevus, facing new Novartis competition, scores FDA nod for more-convenient infusion
Fierce Pharma
Roche
Novartis
Kesimpta
Ocrevus
MS
multiple sclerosis
Flag link:
TG adds a multiple sclerosis string to its bow
TG adds a multiple sclerosis string to its bow
EP Vantage
TG Therapeutics
hematology
ASH2020
ublituximab
MS
multiple sclerosis
Flag link:
MediciNova's Ibudilast Reduces Retinal Thinning in MS Trial Subjects
MediciNova's Ibudilast Reduces Retinal Thinning in MS Trial Subjects
BioSpace
MediciNova
OCT
clinical trials
ibudilast
MS
multiple sclerosis
retinal thinning
Flag link:
GW Pharma Hopes to Bring Its Second Cannabis-Based Drug to Market in the U.S.
GW Pharma Hopes to Bring Its Second Cannabis-Based Drug to Market in the U.S.
BioSpace
GW Pharma
cannabindoids
multiple sclerosis
spasticity
nabiximols
Sativex
Flag link:
Anokion announces FDA clearance of IND application for ANK-700 to treat multiple sclerosis
Anokion announces FDA clearance of IND application for ANK-700 to treat multiple sclerosis
Pharmaceutical Business Review
Anokion
ANK-700
multiple sclerosis
Flag link:
Novartis set to take on Roche as FDA clears first at-home, injectable MS drug
Novartis set to take on Roche as FDA clears first at-home, injectable MS drug
Biopharma Dive
Novartis
FDA
Kesimpta
ofatumumab
MS
multiple sclerosis
Flag link:
Teva shares slide as it faces illegal kickback charges from US government
Teva shares slide as it faces illegal kickback charges from US government
Pharmaforum
Teva Pharmaceutical
kickbacks
DOJ
Copaxone
MS
multiple sclerosis
Flag link:
Mylan launches first generic to Tecfidera in multiple sclerosis
Mylan launches first generic to Tecfidera in multiple sclerosis
Seeking Alpha
Mylan
generics
Tecfidera
Biogen
MS
multiple sclerosis
Flag link:
U.S. court upholds patent for Novartis MS drug Gilenya
U.S. court upholds patent for Novartis MS drug Gilenya
Reuters
Novartis
patents
Gilenya
MS
multiple sclerosis
Flag link:
Sanofi, seeking control of key drug, to buy Principia for $3.7B
Sanofi, seeking control of key drug, to buy Principia for $3.7B
BioPharma Dive
Sanofi
Principia Biopharma
M&A
multiple sclerosis
MS
SAR442168
Flag link:
Immunic's lead MS drug hits primary and key secondary endpoints in PhII, but questions remain
Immunic's lead MS drug hits primary and key secondary endpoints in PhII, but questions remain
Endpoints
Immunic
MS
multiple sclerosis
clinical trials
IMU-838
Flag link:
Biogen points to COVID-19 for disappointing drug launch
Biogen points to COVID-19 for disappointing drug launch
BioPharma Dive
Biogen
Vumerity
MS
multiple sclerosis
Flag link:
Roche, PicnicHealth start RWD partnership with multiple sclerosis focus
Roche, PicnicHealth start RWD partnership with multiple sclerosis focus
MedCity News
Roche
PicnicHealth
MS
multiple sclerosis
RWD
real world data
artificial intelligence
Flag link:
Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases
Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases
Xconomy
Bristol-Meyers Squibb
Dragonfly Therapeutics
multiple sclerosis
MS
neuroinflammation
Flag link:
Mylan, looking to capitalize on Biogen's Tecfidera patent loss, faces fork in the road on generic launch
Mylan, looking to capitalize on Biogen's Tecfidera patent loss, faces fork in the road on generic launch
Fierce Pharma
Biogen
Tecfidera
Mylan
patents
generics
MS
multiple sclerosis
Flag link:
Judge wipes out Biogen's Tecfidera patent protections in suit against Mylan
Judge wipes out Biogen's Tecfidera patent protections in suit against Mylan
Fierce Pharma
Biogen
Mylan
Tecfidera
patents
MS
multiple sclerosis
Flag link:
Bristol Myers Squibb's Zeposia launches into crowded MS market
Bristol Myers Squibb's Zeposia launches into crowded MS market
Fierce Pharma
Bristol-Myers Squibb
Celgene
Zeposia
drug launches
MS
multiple sclerosis
Flag link:
Novartis builds case for MS drug ofatumumab as FDA decision looms
Novartis builds case for MS drug ofatumumab as FDA decision looms
Pharmaforum
Novartis
ofatumumab
clinical trials
MS
multiple sclerosis
Flag link:
Sanofi posts data from contentious phase 2 multiple sclerosis trial
Sanofi posts data from contentious phase 2 multiple sclerosis trial
Fierce Biotech
Sanofi
clinical trials
MS
multiple sclerosis
Principia Biopharma
SAR442168
Flag link:

Pages